Prognostic factors for patients treated with abiraterone
Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evalua...
Shranjeno v:
| Principais autores: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis Group
2020-02-01
|
| Serija: | Future Science OA |
| Teme: | |
| Online dostop: | https://www.future-science.com/doi/10.2144/fsoa-2019-0079 |
| Oznake: |
Brez oznak, prvi označite!
|